Drug Approval | May 12, 2022
OvaCis rapid test to detect ovarian cancer gets CE mark
Revolutionary ovarian cancer rapid test available Q4 2022
Revolutionary ovarian cancer rapid test available Q4 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
Cipla has reported consolidated financial results for the period ended March 31, 2022
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
The new building is expected to be commissioned by 2024. Post the expansion, Nanavati-Max Hospital will be amongst the largest private sector hospital in western India
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
Subscribe To Our Newsletter & Stay Updated
